Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Failed rebound ⢠Support holding Support Level: $7.00-$7.10 Resistance Level: $7.45-$7.50, then $7.80-$8.07 IBRX remains technically weak over the last month, with lower highs, a failed rebound, and sellers currently in control, though holding above $7.00 would be the first sign of stabilization.
Sentiment & News
Key News Insights: ⢠Commercial Momentum ⢠Pipeline Expansion ⢠Valuation Pressure ImmunityBio is showing strong ANKTIVA-driven commercial momentum and a broader immunotherapy pipeline, but the stock now faces valuation scrutiny and dilution risk as investors await key regulatory catalysts.
AI Summary
IBRX has shifted from a pure speculative biotech to a commercialization story driven by ANKTIVA, but after the recent rerating the stock now needs sustained revenue acceleration to offset dilution, litigation, and execution risk.
Description
ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines targeting cancers and infectious diseases. The company applies multiple immunotherapy and cell therapy approachesâincluding engineered cytokine fusion proteins, synthetic immunomodulators, and both natural killer and T-cell platformsâand has candidates in Phase II/III trials for solid and liquid tumors (for example, bladder, pancreatic and lung cancers) as well as antiviral programs for pathogens such as SARS-CoV-2 and HIV. It maintains research collaborations and licensing arrangements with U.S. government institutes and several biopharma partners and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 2 | Mar 9 | IBRX | ImmunityBio, Inc. | ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play. | Closed | -19.1% |
| Feb 19 | Feb 26 | IBRX | ImmunityBio, Inc. | Multiple recent regulatory wins (EU conditional approval for ANKTIVA+BCG on 2026-02-18, Saudi approval, FDA Type B meeting) plus an EU commercialization deal and accelerating product revenue (~$38M quarter) have driven a >200% month-long rally; momentum remains strong into further catalyst and financing headlines despite high risk. | Closed | +10.9% |
| Jan 16 | Jan 23 | IBRX | ImmunityBio, Inc. | ImmunityBio is a hot idea driven by accelerating commercial revenue growth (700% annual increase in 2025), regulatory approvals expanding markets, positive clinical data mid-January 2026, nearly doubled stock price in past month, despite ongoing financial risks. | Closed | +16.9% |